The 10-month mortality rate among older patients treated for digestive system cancer during the first wave of the COVID-19 pandemic: The CADIGCOVAGE multicentre cohort study.

Biliary tract cancer COVID-19 Colorectal cancer Gastric cancer Hepatocellular carcinoma Lockdown Oesophageal cancer Older patients Pancreatic cancer

Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
03 2023
Historique:
received: 14 04 2022
revised: 11 12 2022
accepted: 23 01 2023
pubmed: 30 1 2023
medline: 3 3 2023
entrez: 29 1 2023
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has had a dramatic impact on cancer diagnosis and care pathways. Here, we assessed the mid-term impact of the COVID-19 pandemic on older adults with cancer before, during and after the lockdown period in 2020. We performed a retrospective, observational, multicentre cohort study of prospectively collected electronic health records. All adults aged 65 or over and having been newly treated for a digestive system cancer in our institution between January 2018 until August 2020 were enrolled. Data on 7,881 patients were analyzed. Although the overall 10-month mortality rate was similar in 2020 vs. 2018-2019, the mortality rate among for patients newly treated in the 2020 post-lockdown period was (after four months of follow-up) significantly higher. A subgroup analysis revealed higher mortality rates for (i) patients diagnosed in the emergency department during the pre-lockdown period, (ii) patients with small intestine cancer newly treated during the post-lockdown period, and (iii) patients having undergone surgery with curative intent during the post-lockdown period. However, when considering individuals newly treated during the lockdown period, we observed lower mortality rates for (i) patients aged 80 and over, (ii) patients with a biliary or pancreatic cancer, and (iii) patients diagnosed in the emergency department. There was no overall increase in mortality among patients newly treated in 2020 vs. 2018-2019. Longer follow-up is needed to assess the consequences of the pandemic. A subgroup analysis revealed significant intergroup differences in mortality.

Identifiants

pubmed: 36709553
pii: S1879-4068(23)00035-8
doi: 10.1016/j.jgo.2023.101443
pmc: PMC9883010
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101443

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare no conflicts of interest with regard to this study.

Références

Dig Liver Dis. 2016 Oct;48(10):1112-8
pubmed: 27260332
JAMA Netw Open. 2021 Sep 1;4(9):e2124483
pubmed: 34495337
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
Dig Liver Dis. 2022 Jan;54(1):10-18
pubmed: 34654679
Lancet Oncol. 2021 Nov;22(11):1507-1517
pubmed: 34624250
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Int J Cancer. 2022 May 15;150(10):1609-1618
pubmed: 35001364
Med Care. 2016 Feb;54(2):188-94
pubmed: 26683778
Oncologist. 2021 Feb;26(2):e338-e341
pubmed: 33111460
Clin Colorectal Cancer. 2022 Jun;21(2):e117-e125
pubmed: 34953674
Dig Liver Dis. 2020 Jun;52(6):597-603
pubmed: 32418773
Oncologist. 2019 Dec;24(12):e1351-e1359
pubmed: 31324663
Lancet Oncol. 2020 Jun;21(6):748-750
pubmed: 32359404
PLoS One. 2021 Dec 9;16(12):e0260381
pubmed: 34882700
Lancet Gastroenterol Hepatol. 2021 May;6(5):342-343
pubmed: 33857441
Dig Liver Dis. 2014 Feb;46(2):97-104
pubmed: 23796552
J Geriatr Oncol. 2020 Nov;11(8):1190-1198
pubmed: 32709495

Auteurs

Thomas Aparicio (T)

AP-HP, Saint Louis Hospital, Gastroenterology and Digestive Oncology Department, F-75010 Paris, France; Université de Paris, F-75000 Paris, France. Electronic address: thomas.aparicio@aphp.fr.

Richard Layese (R)

AP-HP, Henri-Mondor Hospital, Public Health and Clinical Research department (URC Mondor), F-94010 Créteil, France; Univ Paris Est Creteil, INSERM, IMRB U955, F-94000 Creteil, France.

François Hemery (F)

AP-HP, Henri-Mondor Hospital, Medical Information Departement, F-94010 Créteil, France.

Christophe Tournigand (C)

AP-HP, Henri-Mondor Hospital, Medical Oncology Department, F-94010 Créteil, France.

Elena Paillaud (E)

Univ Paris Est Creteil, INSERM, IMRB U955, F-94000 Creteil, France; AP-HP, Paris Cancer Institute CARPEM, Georges Pompidou Hospital, Geriatric Department, F-75015 Paris, France.

Nicola De Angelis (N)

AP-HP, Henri-Mondor Hospital, Digestive Surgery, F-94010 Créteil, France.

Laurent Quero (L)

Université de Paris, F-75000 Paris, France; AP-HP, Saint Louis Hospital, Radiotherapy Department, F-75010 Paris, France.

Nathalie Ganne (N)

AP-HP, Avicenne Hospital, Hepatology Department, F-93000 Bobigny, France.

Fredéric Prat (F)

Université de Paris, F-75000 Paris, France; AP-HP, Beaujon Hospital, Endoscopy Department, F-92110 Clichy, France.

Atanas Pachev (A)

AP-HP, Saint Louis Hospital, Radiology Department, F-75010 Paris, France.

Gilles Galula (G)

AP-HP, Tenon Hospital, Medical Oncology, F-75020 Paris, France.

Marc-Antoine Benderra (MA)

AP-HP, Tenon Hospital, Medical Oncology, F-75020 Paris, France.

Florence Canouï-Poitrine (F)

AP-HP, Henri-Mondor Hospital, Public Health and Clinical Research department (URC Mondor), F-94010 Créteil, France; Univ Paris Est Creteil, INSERM, IMRB U955, F-94000 Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH